Noah Stansfield

No dose-limiting toxicities were observed at 28 days of follow-up.

Nearly half of participants were able to engage in normal physical activity without angina at 6 months post-treatment.

Patients continued to show statistically significant upper limb performance improvements.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The dosing of the first patient took place in December 2022 and no adverse events related to the therapy have been reported.

No patients treated with Tevogen Bio’s TVGN 489 showed progression of their COVID-19 infections.

REGENXBIO has also initiated recruitment for AFFINITY BEYOND, an observational study assessing the prevalence of AAV8 antibodies in male patients with DMD.

The overall response rate was 44% among 16 patients with synovial sarcoma.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Forge Biologics’ FBX-101 previously demonstrated promising safety and efficacy in early data from the phase 1/2 RESKUE clinical trial.

Of the 20 mice treated with the experimental approach, 19 achieved clearance of residual tumor cells.

Poolbeg Pharma’s POLB 001 previously showed promise in a lipopolysaccharide human challenge trial.

Seelos Therapeutics’ SLS-004 showed the ability to downregulate α-synuclein, and CENTOGENE’s ROPAD study will be extended.

Several phase 3 trials for AlloVir’s posoleucel are expected to complete enrollment in 2023.

Tenaya Therapeutics expects the dosing of the first patient in the planned phase 1b trial in Q3 2023.

The trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of B4t2-001.

The FDA made the decision in response to manufacturing process information that it considered a major amendment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Instil Bio, ITIL-306’s developer, expects to present initial data from the phase 1 trial’s dose escalation cohorts this year.

Some patients previously treated with GNT-003 were able to maintain the stoppage of phototherapy for at least 1 year.

No serious adverse events related to the gene therapy have been reported.

The company expects to provide initial data from the trial in the second half of this year.

Promising results were previously reported from a proof-of-concept study involving 8 patients.

The first patient dosed in the study experienced a case of prolonged pancytopenia that has required ongoing transfusion and growth factor support.

Initial data from the trials of HMI-103 and HMI-203 are expected in 2023.

Allocetra previously demonstrated efficacy in a phase 1b trial for patients with sepsis.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CT103A is currently being evaluated in multiple clinical trials in China.

The company is seeking out other companies to continue development of its autologous CAR-T platform.

The CR was achieved at 1-month post-treatment.